lisdexamfetamine dimesylate Articles
Positive response from European regulatory procedure supports Shire's Elvanse for ADHD
18 December 2012
FDA accepts Shire's sNDA for Vyvanse as maintenance treatment
12 September 2012
Global ADHD market set to grow at a CAGR of 8% to 2018
14 December 2011
Generic erosion will see ADHD drug market fall from $5 billion in 2009 to $4.1 billion in 2019
7 December 2010
US FDA approves Eisai’s Halaven for metastatic breast cancer and expanded use for Shire’s Vyvanse
16 November 2010
Merck & Co prevails in Temodar law suit against Barr/Teva on appeal; Court upholds Shire’s Vyvanse exclusivity
11 November 2010
US Court upholds FDA’s grant of five-year market exclusivity for Shire’s ADHD drug Vyvanse
5 March 2010
Shire’s fourth-quarter 2009 earnings significantly beat expectations
22 February 2010
Shire’s new drugs offset slumping Adderall in 3rd quarter 2009
2 November 2009
Shire sales up 20% pre-Adderall demise
1 May 2009
GSK/Shire Vyvanse deal fuels speculation
1 April 2009
Stock Commentary - Europe - week to Jan 19, 2009
26 January 2009
Shire's HGT unveils ambitious growth plan, doubling sales contribution to 30% by 2015
1 December 2008
3rd-qtr new product sales deliver for Shire, but the firm posts earnings drop on charges
10 November 2008
Shire's Vyvanse projected to gain blockbuster status by 2017
13 October 2008
Stock Commentary - Europe - week to Oct 6, 2008
13 October 2008
Shire ups forecast on strong 2nd qtr
11 August 2008
Shire's Vyvanse improves ADHD in adults
19 May 2008
Shire: strong 1st qtr, wary over new drug
5 May 2008
Shire's Vyvanse cleared for ADHD in adults
28 April 2008
LB analysts: Shire is "heavily" over-valued
31 March 2008
Is Pfizer eyeing up UK's Shire for acquisition?
24 March 2008
Stock Commentary - Europe - week to Feb 25, 2008
3 March 2008
Stock Commentary - Europe - week to Feb 11, 2008
18 February 2008
Stock Commentary - Europe - week to Feb 4, 2008
11 February 2008
Shire posts "best ever" results
12 November 2007
Shire's Vyvanse made available in USA
6 August 2007
Stock Commentary - Europe - week to July 9, 2007
16 July 2007
Shire submits sNDA for Vyvanse to US FDA
9 July 2007
Vyvanse classified as Schedule II by US DEA
14 May 2007
Shire's 1st-qtr income soars 85% on sales
7 May 2007
New River's FY 2006 loss deepens to $57M
26 March 2007
Shire's proposed purchase of New River progresses
26 March 2007
Stock Commentary - Europe - week to March 5, 2007
12 March 2007
Shire secures successor to Adderall XR as US FDA approves Vyvanse: another predicted blockbuster
5 March 2007
Shire to purchase New River for $2.6B in cash
26 February 2007
Shire's 2006 income hits $278M, sales up 16%
26 February 2007
Vyvanse receives 2nd FDA approvable letter
8 January 2007
New River updates on NRP290
23 October 2006
Showing 1-56 of 56 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
